Wedbush analyst David Nierengarten raised the firm’s price target on AnaptysBio (ANAB) to $70 from $45 and keeps an Outperform rating on the shares. The firm notes that at an R&D Day, AnaptysBio detailed clinical development plans for CD122 antagonist mAb ANB033 in celiac disease, and highlighted a possible expansion into eosinophilic esophagitis. Importantly, the CeD trial will feature two cohorts: in addition to an expected cohort evaluating protection against gluten challenge, a second cohort will recruit patients with higher VH:CD ratios to test the ability of ANB033 to heal existing mucosal damage. Topline results are expected by year-end 2026, Wedbush adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- Positive Outlook for AnaptysBio: Strategic Developments and Promising Trial Results Drive Buy Rating
- AnaptysBio initiated with an Overweight at Barclays
- Trump announces lumber tariffs, Exxon Mobil to cut 2,000 jobs: Morning Buzz
- Strategic Split and Promising Pipeline: AnaptysBio’s Path to Growth and Value Maximization
- AnaptysBio price target raised to $59 from $38 at H.C. Wainwright